Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil
Obesity is among the most alarming health concerns, impacting public health and causing a socioeconomic challenge, especially in developing countries like Brazil, where approximately one quart of the population presents obesity. As an established risk factor for numerous comorbidities with a multifa...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/13/6/2027 |
_version_ | 1797530424772132864 |
---|---|
author | Ligia M. Watanabe Anderson M. Navarro Lucia A. Seale |
author_facet | Ligia M. Watanabe Anderson M. Navarro Lucia A. Seale |
author_sort | Ligia M. Watanabe |
collection | DOAJ |
description | Obesity is among the most alarming health concerns, impacting public health and causing a socioeconomic challenge, especially in developing countries like Brazil, where approximately one quart of the population presents obesity. As an established risk factor for numerous comorbidities with a multifactorial etiology, obesity is a consequence of energy-dense overfeeding, however with significant undernourishment, leading to excessive adipose tissue accumulation and dysfunction, dyslipidemia, and micronutrient deficiencies. About 60% of patients with obesity take statins, a cholesterol-lowering medication, to curb dyslipidemia, with ~10% of these patients presenting various myopathies as side effects. Statins act upon the rate-limiting enzyme of cholesterol biosynthesis in the liver, which is a pathway providing intermediates to the synthesis of selenoproteins, i.e., enzymes containing the micronutrient selenium. Statins have been postulated to negatively impact selenoprotein synthesis, particularly in conditions of selenium deficiency, and potentially implicated in the myopathies occurring as side effects of statins. The Brazilian population is prone to selenium deficiency, hence could be considered more susceptible to statin side effects. This review examines the specific consequences to the Brazilian population of the harmful intersection between obesity development and concomitant micronutrient deficiencies, particularly selenium, combined with statin treatment in the context of nutrition in Brazil. |
first_indexed | 2024-03-10T10:28:45Z |
format | Article |
id | doaj.art-e166ed04d5714a429981d1362f97a535 |
institution | Directory Open Access Journal |
issn | 2072-6643 |
language | English |
last_indexed | 2024-03-10T10:28:45Z |
publishDate | 2021-06-01 |
publisher | MDPI AG |
record_format | Article |
series | Nutrients |
spelling | doaj.art-e166ed04d5714a429981d1362f97a5352023-11-21T23:51:05ZengMDPI AGNutrients2072-66432021-06-01136202710.3390/nu13062027Intersection between Obesity, Dietary Selenium, and Statin Therapy in BrazilLigia M. Watanabe0Anderson M. Navarro1Lucia A. Seale2Department of Health Sciences, Division of Nutrition and Metabolism, Ribeirão Preto Medical School, University of São Paulo—FMRP/USP, Ribeirão Preto 14040-900, SP, BrazilDepartment of Health Sciences, Division of Nutrition and Metabolism, Ribeirão Preto Medical School, University of São Paulo—FMRP/USP, Ribeirão Preto 14040-900, SP, BrazilPacific Biosciences Research Center, School of Ocean and Earth Science and Technology, University of Hawaii at Manoa, Honolulu, HI 96822, USAObesity is among the most alarming health concerns, impacting public health and causing a socioeconomic challenge, especially in developing countries like Brazil, where approximately one quart of the population presents obesity. As an established risk factor for numerous comorbidities with a multifactorial etiology, obesity is a consequence of energy-dense overfeeding, however with significant undernourishment, leading to excessive adipose tissue accumulation and dysfunction, dyslipidemia, and micronutrient deficiencies. About 60% of patients with obesity take statins, a cholesterol-lowering medication, to curb dyslipidemia, with ~10% of these patients presenting various myopathies as side effects. Statins act upon the rate-limiting enzyme of cholesterol biosynthesis in the liver, which is a pathway providing intermediates to the synthesis of selenoproteins, i.e., enzymes containing the micronutrient selenium. Statins have been postulated to negatively impact selenoprotein synthesis, particularly in conditions of selenium deficiency, and potentially implicated in the myopathies occurring as side effects of statins. The Brazilian population is prone to selenium deficiency, hence could be considered more susceptible to statin side effects. This review examines the specific consequences to the Brazilian population of the harmful intersection between obesity development and concomitant micronutrient deficiencies, particularly selenium, combined with statin treatment in the context of nutrition in Brazil.https://www.mdpi.com/2072-6643/13/6/2027obesityseleniumBrazilstatins |
spellingShingle | Ligia M. Watanabe Anderson M. Navarro Lucia A. Seale Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil Nutrients obesity selenium Brazil statins |
title | Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil |
title_full | Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil |
title_fullStr | Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil |
title_full_unstemmed | Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil |
title_short | Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil |
title_sort | intersection between obesity dietary selenium and statin therapy in brazil |
topic | obesity selenium Brazil statins |
url | https://www.mdpi.com/2072-6643/13/6/2027 |
work_keys_str_mv | AT ligiamwatanabe intersectionbetweenobesitydietaryseleniumandstatintherapyinbrazil AT andersonmnavarro intersectionbetweenobesitydietaryseleniumandstatintherapyinbrazil AT luciaaseale intersectionbetweenobesitydietaryseleniumandstatintherapyinbrazil |